Article Details

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL ... - PR Newswire

Retrieved on: 2022-07-04 00:11:17

Tags for this article:

Click the tags to see associated articles and topics

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL ... - PR Newswire. View article details on hiswai:

Excerpt

IBI112, a novel anti-IL-23p19 monoclonal antibody developed by ... In terms of biologics, anti-TNF-α Monoclonal antibodies have problems such as ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up